Your browser doesn't support javascript.
Esketamine for treatment resistant depression: a trick of smoke and mirrors?
Epidemiol Psychiatr Sci ; 29: e79, 2019 Dec 16.
Artigo em Inglês | MEDLINE | ID: mdl-31841104
ABSTRACT
In March 2019, the US Food and Drug Administration (FDA) approved a nasal spray formulation of esketamine for the treatment of resistant depression in adults. Esketamine is the S-enantiomer of ketamine, an FDA-approved anaesthetic, known to cause dissociation and, occasionally, hallucinations. While ketamine has not been approved for depression in the USA or in any other country, it has been used off-label in cases of severe depression. This commentary critically reviewed the evidence on esketamine submitted to the FDA, aiming to draw implications for clinical practice, research and regulatory science.
Assuntos

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Depressão / Transtorno Depressivo Resistente a Tratamento / Ketamina / Antidepressivos Aspecto clínico: Terapia Limite: Adulto / Humanos País/Região como assunto: América do Norte Idioma: Inglês Revista: Epidemiol Psychiatr Sci Ano de publicação: 2019 Tipo de documento: Artigo País de afiliação: Itália